Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IL-5 biologics in severe eosinophilic asthma with comorbid bronchiectasis
NL-OMON20373Recruiting
- Sponsor
- No
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of mepolizumab, reslizumab and benralizumab in eosinophilic asthma (EA) and bronchiectasis (2 arms), sponsored by No. Primary endpoints: Change in daily oral corticosteroid dose, Change in annualized exacerbation rate and 1 more. Started Oct 2021; status: recruiting.
02
Drugs
mepolizumabreslizumabbenralizumab
03
Conditions
eosinophilic asthma (EA)bronchiectasis
Beyond the preview
Go deeper on NL-OMON20373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20373.